Pyrimidine derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors

1. A compound of formula (Ia):

wherein:

Ra is a hydrogen atom or an alkyl radical;

R1a is a hydrogen atom or a methyl radical;

R2a is a hydrogen atom or a fluorine atom;

R3a is a hydrogen atom or a halogen atom;

R4a is a hydrogen atom, a halogen atom or a hydroxyl, alkyl or alkoxy radical, the alkyl radicals being optionally substituted with one or more radicals, which may be identical or different, selected from halogen atoms and the hydroxyl radical, the alkoxy radicals being optionally substituted with one or more halogen atoms;

R5a and R5′a, which may be identical or different, are a hydrogen atom or an alkyl radical;

R6a is a hydrogen atom or an alkyl radical optionally substituted with one or more radicals, which may be identical or different, selected from halogen atoms and the hydroxyl radical;

R7a is a halogen atom;

or a racemic, enantiomeric or diastereoisomeric isomer form, or an addition salt with inorganic and organic acids or with inorganic and organic bases of said compound of formula (Ia).

2. The compound of formula (Ia) as defined in claim 1 , selected from the group consisting of:

-5-fluoro-2-[2-(4-fluoro-2,3-dihydro-1H-indol-1-yl)-2-oxoethyl]-6-(morpholin-4-yl)pyrimidin-4(3H)-one;

-5-fluoro-2-[2-(4-fluoro-2,3-dihydro-1H-indol-1-yl)-2-oxoethyl]-3-methyl-6-(morpholin-4-yl)pyrimidin-4(3H)-one;

-5-fluoro-2-[1-(4-fluoro-2,3-dihydro-1H-indol-1-yl)-1-oxopropan-2-yl]-3-methyl-6-(morpholin-4-yl)pyrimidin-4(3H)-one;

-5-fluoro-2-{2-[(2R)-2-methyl-2,3-dihydro-1H-indol-1-yl]-2-oxoethyl}-6-(morpholin-4-yl)pyrimidin-4(3H)-one;

-5-fluoro-2-{2-[(2S)-2-methyl-2,3-dihydro-1H-indol-1-yl]-2-oxoethyl}-6-(morpholin-4-yl)pyrimidin-4(3H)-one;

-5-fluoro-2-{2-[(2R)-5-fluoro-2-methyl-2,3-dihydro-1H-indol-1-yl]-2-oxoethyl}-6-(morpholin-4-yl)pyrimidin-4(3H)-one;

-5-fluoro-2-{2-[(2S)-5-fluoro-2-methyl-2,3-dihydro-1H-indol-1-yl]-2-oxoethyl}-6-(morpholin-4-yl)pyrimidin-4(3H)-one;

-5-fluoro-3-methyl-2-{2-[(2S)-2-methyl-2,3-dihydro-1H-indol-1-yl]-2-oxoethyl}-6-(morpholin-4-yl)pyrimidin-4(3H)-one;

-5-fluoro-3-methyl-2-{2-[(2R)-2-methyl-2,3-dihydro-1H-indol-1-yl]-2-oxoethyl}-6-(morpholin-4-yl)pyrimidin-4(3H)-one;

-5-fluoro-2-{2-[(2R)-4-fluoro-2-methyl-2,3-dihydro-1H-indol-1-yl]-2-oxoethyl}-6-(morpholin-4-yl)pyrimidin-4(3H)-one;

-5-fluoro-2-{2-[(2S)-4-fluoro-2-methyl-2,3-dihydro-1H-indol-1-yl]-2-oxoethyl}-6-(morpholin-4-yl)pyrimidin-4(3H)-one;

-2-{2-[(2S)-5,6-difluoro-2-methyl-2,3-dihydro-1H-indol-1-yl]-2-oxoethyl}-5-fluoro-6-(morpholin-4-yl)pyrimidin-4(3H)-one;

-2-{2-[(2R)-5,6-difluoro-2-methyl-2,3-dihydro-1H-indol-1-yl]-2-oxoethyl}-5-fluoro-6-(morpholin-4-yl)pyrimidin-4(3H)-one;

-5-fluoro-2-{2-[(2S)-5-fluoro-2-methyl-2,3-dihydro-1H-indol-1-yl]-2-oxoethyl}-3-methyl-6-(morpholin-4-yl)pyrimidin-4(3H)-one;

-5-fluoro-2-{2-[(2R)-5-fluoro-2-methyl-2,3-dihydro-1H-indol-1-yl]-2-oxoethyl}-3-methyl-6-(morpholin-4-yl)pyrimidin-4(3H)-one;

-2-{2-[(2R)-4-bromo-2-methyl-2,3-dihydro-1H-indol-1-yl]-2-oxoethyl}-5-fluoro-6-(morpholin-4-yl)pyrimidin-4(3H)-one;

-2-{2-[(2S)-4-bromo-2-methyl-2,3-dihydro-1H-indol-1-yl]-2-oxoethyl}-5-fluoro-6-(morpholin-4-yl)pyrimidin-4(3H)-one;

-2-{2-[(2R)-4-chloro-2-methyl-2,3-dihydro-1H-indol-1-yl]-2-oxoethyl}-5-fluoro-6-(morpholin-4-yl)pyrimidin-4(3H)-one;

-2-{2-[(2S)-4-chloro-2-methyl-2,3-dihydro-1H-indol-1-yl]-2-oxoethyl}-5-fluoro-6-(morpholin-4-yl)pyrimidin-4(3H)-one;

-2-{2-[(2R)-4,5-difluoro-2-methyl-2,3-dihydro-1H-indol-1-yl]-2-oxoethyl}-5-fluoro-6-(morpholin-4-yl)pyrimidin-4(3H)-one;

-2-{2-[(2S)-4,5-difluoro-2-methyl-2,3-dihydro-1H-indol-1-yl]-2-oxoethyl}-5-fluoro-6-(morpholin-4-yl)pyrimidin-4(3H)-one;

-5-fluoro-2-{2-[(2S)-4-fluoro-2-methyl-2,3-dihydro-1H-indol-1-yl]-2-oxoethyl}-3-methyl-6-(morpholin-4-yl)pyrimidin-4(3H)-one;

-5-fluoro-2-{2-[(2R)-4-fluoro-2-methyl-2,3-dihydro-1H-indol-1-yl]-2-oxoethyl}-3-methyl-6-(morpholin-4-yl)pyrimidin-4(3H)-one;

-2-{2-[(2R)-4,5-difluoro-2-methyl-2,3-dihydro-1H-indol-1-yl]-2-oxoethyl}-5-fluoro-3-methyl-6-(morpholin-4-yl)pyrimidin-4(3H)-one;

-2-{2-[(2S)-4,5-difluoro-2-methyl-2,3-dihydro-1H-indol-1-yl]-2-oxoethyl}-5-fluoro-3-methyl-6-(morpholin-4-yl)pyrimidin-4(3H)-one;

-2-{2-[(2R)-5,6-difluoro-2-methyl-2,3-dihydro-1H-indol-1-yl]-2-oxoethyl}-5-fluoro-3-methyl-6-(morpholin-4-yl)pyrimidin-4(3H)-one;

-2-{2-[(2S)-5,6-difluoro-2-methyl-2,3-dihydro-1H-indol-1-yl]-2-oxoethyl}-5-fluoro-3-methyl-6-(morpholin-4-yl)pyrimidin-4(3H)-one;

-2-{2-[(2R)-4-chloro-2-methyl-2,3-dihydro-1H-indol-1-yl]-2-oxoethyl}-5-fluoro-3-methyl-6-(morpholin-4-yl)pyrimidin-4(3H)-one;

-2-{2-[(2S)-4-chloro-2-methyl-2,3-dihydro-1H-indol-1-yl]-2-oxoethyl}-5-fluoro-3-methyl-6-(morpholin-4-yl)pyrimidin-4(3H)-one;

-2-{2-[(2R)-4-bromo-2-methyl-2,3-dihydro-1H-indol-1-yl]-2-oxoethyl}-5-fluoro-3-methyl-6-(morpholin-4-yl)pyrimidin-4(3H)-one;

-2-{2-[(2S)-4-bromo-2-methyl-2,3-dihydro-1H-indol-1-yl]-2-oxoethyl}-5-fluoro-3-methyl-6-(morpholin-4-yl)pyrimidin-4(3H)-one;

-5-fluoro-2-{2-[(2S)-6-fluoro-2-methyl-2,3-dihydro-1H-indol-1-yl]-2-oxoethyl}-6-(morpholin-4-yl)pyrimidin-4(3H)-one;

-5-fluoro-2-{2-[(2R)-6-fluoro-2-methyl-2,3-dihydro-1H-indol-1-yl]-2-oxoethyl}-6-(morpholin-4-yl)pyrimidin-4(3H)-one;

-5-chloro-2-{2-[(2R)-2-methyl-2,3-dihydro-1H-indol-1-yl]-2-oxoethyl}-6-(morpholin-4-yl)pyrimidin-4(3H)-one;

-5-chloro-2-{2-[(2S)-2-methyl-2,3-dihydro-1H-indol-1-yl]-2-oxoethyl}-6-(morpholin-4-yl)pyrimidin-4(3H)-one;

-2-{2-[4-chloro-5-fluoro-2-methyl-2,3-dihydro-1H-indol-1-yl]-2-oxoethyl}-5-fluoro-3-methyl-6-(morpholin-4-yl)pyrimidin-4(3H)-one;

-5-bromo-2-[2-((S)-2-methyl-2,3-dihydroindol-1-yl)-2-oxoethyl]-6-morpholin-4-yl-3H-pyrimidin-4-one;

-5-fluoro-2-[2-((+)-2-hydroxymethyl-2,3-dihydroindol-1-yl)-2-oxoethyl]-6-morpholin-4-yl-3H-pyrimidin-4-one; and

-5-fluoro-2-[2-((−)-2-hydroxymethyl-2,3-dihydroindol-1-yl)-2-oxoethyl]-6-morpholin-4-yl-3H-pyrimidin-4-one;

or a racemic, enantiomeric or diastereoisomeric isomer form, or an addition salt with inorganic and organic acids or with inorganic and organic bases of said compound of formula (Ia).

3. A compound of formula (Ie):

wherein:

Xe and Ye, which may be identical or different, are such that:

Xe is O or S and Ye is S;

Re is a hydrogen atom or an alkyl radical;

R1e is a hydrogen atom or a methyl radical;

R2e is a hydrogen atom or a fluorine atom;

R3e is a hydrogen atom or a halogen atom;

R4e is a hydrogen atom, a halogen atom or a hydroxyl, alkyl or alkoxy radical, the alkyl radicals being optionally substituted with one or more radicals, which may be identical or different, selected from halogen atoms and the hydroxyl radical, the alkoxy radicals being optionally substituted with one or more halogen atoms;

R5e and R5′e, which may be identical or different, are a hydrogen atom or an alkyl radical;

R6e is a hydrogen atom or an alkyl radical optionally substituted with one or more radicals, which may be identical or different, selected from halogen atoms and the hydroxyl radical;

R7e is a hydrogen atom or a halogen atom;

or a racemic, enantiomeric or diastereoisomeric isomer form, or an addition salt with inorganic and organic acids or with inorganic and organic bases of said compound of formula (Ie).

4. The compound of formula (Ie) as defined in claim 3 selected from the group consisting of:

-1-((S)-2-methyl-2,3-dihydroindol-1-yl)-2-(4-morpholin-4-yl-6-thioxo-1,6-dihydropyrimidin-2-yl)ethanone;

-1-((R)-2-methyl-2,3-dihydroindol-1-yl)-2-(4-morpholin-4-yl-6-thioxo-1,6-dihydropyrimidin-2-yl)ethanone;

-2-[2-((S)-2-methyl-2,3-dihydroindol-1-yl)-2-thioxoethyl]-6-morpholin-4-yl-3H-pyrimidine-4-thione;

-1-((S)-2-methyl-2,3-dihydroindol-1-yl)-2-(1-methyl-4-morpholin-4-yl-6-thioxo-1,6-dihydropyrimidin-2-yl)ethanone;

-1-((R)-2-methyl-2,3-dihydroindol-1-yl)-2-(1-methyl-4-morpholin-4-yl-6-thioxo-1,6-dihydropyrimidin-2-yl)ethanone;

-1-(4-fluoro-2,3-dihydroindol-1-yl)-2-(1-methyl-4-morpholin-4-yl-6-thioxo-1,6-dihydropyrimidin-2-yl)ethanone;

-1-(4-chloro-2,3-dihydroindol-1-yl)-2-(1-methyl-4-morpholin-4-yl-6-thioxo-1,6-dihydropyrimidin-2-yl)ethanone;

-1-((+)-4,5-difluoro-2-methyl-2,3-dihydroindol-1-yl)-2-(5-fluoro-4-morpholin-4-yl-6-thioxo-1,6-dihydropyrimidin-2-yl)ethanone;

-2-[2-((+)-4,5-difluoro-2-methyl-2,3-dihydroindol-1-yl)-2-thioxoethyl]-5-fluoro-6-morpholin-4-yl-3H-pyrimidine-4-thione;

-2-(5-fluoro-4-morpholin-4-yl-6-thioxo-1,6-dihydropyrimidin-2-yl)-1-((S)-2-methyl-2,3-dihydroindol-1-yl)ethanone; and

-2-(5-fluoro-4-morpholin-4-yl-6-thioxo-1,6-dihydropyrimidin-2-yl)-1-((R)-2-methyl-2,3-dihydroindol-1-yl)ethanone;

or a racemic, enantiomeric or diastereoisomeric isomer form, or an addition salt with inorganic and organic acids or with inorganic and organic bases of said compound of formula (Ie).

5. A medicament comprising the compound of formula (Ia) as defined in claim 1 or a racemic, enantiomeric or diastereoisomeric isomer form or a pharmaceutically acceptable addition salt with inorganic and organic acids or with inorganic and organic bases of said compound of formula (Ia).

6. A pharmaceutical composition comprising, as active ingredient, the compound of formula (Ia) as defined in claim 1 or a pharmaceutically acceptable addition salt with inorganic and organic acids or with inorganic and organic bases of said compound or a prodrug of said compound and a pharmaceutically acceptable support.

7. A method of treatment of cancer comprising administering to a patient in need of such treatment a therapeutically effective amount of the compound of formula (Ia), or a racemic, enantiomeric and diastereoisomeric isomer form, or an addition salt with inorganic and organic acids or with inorganic and organic bases of said compound of formula (Ia), as defined in claim 1 , wherein said cancer is selected from primary prostate tumors and/or metastases of prostate cancer and primary ovarian tumors and/or metastases of ovarian cancer.

8. The method according to claim 7 wherein said cancer is resistant to cytotoxic agents.

9. A medicament comprising the compound of formula (Ie) as defined in claim 3 or a racemic, enantiomeric or diastereoisomeric isomer form or a pharmaceutically acceptable addition salt with inorganic and organic acids or with inorganic and organic bases of said compound of formula (Ie).

10. A pharmaceutical composition comprising, as active ingredient, the compound of formula (Ie) as defined in claim 3 or a pharmaceutically acceptable addition salt of said compound with inorganic and organic acids or with inorganic and organic bases or a prodrug of said compound and a pharmaceutically acceptable support.

11. A method of treatment of cancer comprising administering to a patient in need of such treatment a therapeutically effective amount of the compound of formula (Ie), or a racemic, enantiomeric and diastereoisomeric isomer form, or an addition salt with inorganic and organic acids or with inorganic and organic bases of said compound of formula (Ia), as defined in claim 3 , wherein said cancer is selected from primary prostate tumors and/or metastases of prostate cancer and primary ovarian tumors and/or metastases of ovarian cancer.

12. The method according to claim 11 wherein said cancer is resistant to cytotoxic agents.